利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

54 条记录 (耗时 0.014 秒)

    USE OF ALGINATE COMPOSITIONS IN PREVENTING OR REDUCING LIVER DAMAGE CAUSED BY A HEPATOTOXIC AGENT
    1.
    发明公开
    USE OF ALGINATE COMPOSITIONS IN PREVENTING OR REDUCING LIVER DAMAGE CAUSED BY A HEPATOTOXIC AGENT 审中-公开
    海藻成分对防止或减少肝损伤BY HEPATOTOXIKA USE

    公开(公告)号：EP2938347A4

    公开(公告)日：2016-08-10

    申请号：EP13869473

    申请日：2013-12-30

    申请人： HADASIT MED RES SERVICE ,  B G NEGEV TECHNOLOGIES & APPLIC LTD AT BEN GURION UNIVERSITY

    发明人： COHEN SMADAR ,  ILAN YARON ,  SHTEYER EYAL ,  BEN-YA ACOV AMI

    IPC分类号： A61K31/734 ,  A61K31/738 ,  A61P1/16

    CPC分类号： A61K31/734 ,  A61K9/0053 ,  A61K31/167 ,  A61K45/06 ,  A61K2300/00

    摘要： Compositions comprising an alginate, a source of sodium ions and a carrier (e.g., a pharmaceutically acceptable carrier), which are characterized by reduced association of the alginate chains and hence by at least one of: (i) a zeta potential weaker than −25 mV, at a concentration of 0.5% (w/v) alginate in the carrier; and (ii) a diffusion coefficient of at least 10−8 cm2/millisecond, at a concentration of 0.5% (w/v) alginate in the carrier, are disclosed. Also disclosed are uses of the composition and methods utilizing the composition for treating inflammatory bowel disease, liver damage, diseases and disorders, for treating a medical condition treatable by a hepatotoxic agent and for reducing or preventing liver damage, including liver damage caused by a hepatotoxic agent.

    摘要翻译： 组合物包含藻酸盐的，钠离子源和载体（例如，药学上可接受的载体），这是由藻酸盐链的缔合减少表征并因此，通过中的至少一个：（i）的ζ电位弱于-25 毫伏，以0.5％（W / v）在载体的藻酸盐的浓度; 和（ⅱ）至少10-8厘米2 /毫秒的扩散系数，以0.5％的浓度（重量/体积）在载体藻酸盐，是游离缺失盘。 所以游离缺失盘是所述组合物的用途和利用用于治疗炎性肠疾病，肝损伤，疾病和病症中，用于治疗医学病症可治疗由肝毒性药剂和用于减少或预防肝功能损害，包括由肝毒性肝损伤的组合物的方法 剂。

    COMPOSITION AND METHOD FOR TREATING OR PREVENTING SKELETAL MUSCLE FIBROSIS
    5.
    发明公开
    COMPOSITION AND METHOD FOR TREATING OR PREVENTING SKELETAL MUSCLE FIBROSIS 有权
    组合物和方法用于治疗或预防骨骼肌纤维化

    公开(公告)号：EP2114409A4

    公开(公告)日：2010-09-01

    申请号：EP08702669

    申请日：2008-01-21

    申请人： AGRICULTURAL RES ORG ,  HADASIT MED RES SERVICE

    发明人： PINES MARK ,  NAGLER ARNON

    IPC分类号： A61K31/519

    CPC分类号： A61K31/517

    摘要： A compound in combination with a pharmaceutically acceptable carrier, the compound having a formula: wherein: R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy; R2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy; and R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl; and n is either 1 or 2; and pharmaceutically acceptable salts thereof; for use in treatment of or prevention of skeletal muscle fibrosis and/or for inducing skeletal muscle regeneration.

    CONDITIONING FOR ALLOGENEIC STEM CELL TRANSPLANTATION
    8.
    发明公开
    CONDITIONING FOR ALLOGENEIC STEM CELL TRANSPLANTATION 失效
    BEHANDLUNG ZUR ALLOGENEN STAMMZELLTRANSPLANTATION

    公开(公告)号：EP1011694A4

    公开(公告)日：2000-11-15

    申请号：EP97949457

    申请日：1997-11-14

    申请人： BAXTER INT ,  HADASIT MED RES SERVICE

    发明人： SLAVIN SHIMON

    IPC分类号： A61K35/12 ,  A61K35/14 ,  A61K35/28 ,  A61K38/00 ,  A61P43/00 ,  C12N5/0783 ,  C12N5/0789

    CPC分类号： C12N5/0636 ,  A61K35/17 ,  A61K35/28 ,  A61K38/00 ,  A61K2035/122 ,  A61K2035/124 ,  C12N5/0647

    摘要： Serious hematologic malignancies are treated through high dose or lethal chemotherapy and/or radiation therapy conditioning regimens followed by rescue with allogeneic stem cell transplantation (allo-SCT) or autologous stem cell transplantation (ASCT). These myeloablative/lymphoablative (M/L) treatment regimens involve the elimination of both the patient's hematopoietic stem cells and T-lymphocytes, often leading to serious complications including graft versus host disease (GVHD). The claimed invention addresses some of these problems by providing a conditioning regimen that is designed to eliminate the patient's T-lymphocytes while retaining a functional population of hematopoietic stem cells (HSC). This non-myeloablative/lymphoablative (-/L) conditioning regimen involves the administration of one or more agents such as purine analogs (e.g., fludarabine), alkylating agents (e.g., bisulfan, cyclophosphamide), or anti-leukocyte globulins (e.g., anti-T lymphocyte globulin). After this, a donor-derived allogeneic stem cell preparation is administered to the patient. Patients treated according to the claimed invention develop donor-specific unresponsiveness and relatively fewer complications as compared to standard M/L conditioning regimens. The claimed methodologies should prove useful in the treatment of a number of hematologic malignancies such as chronic myelogenous leukemia, acute myelogenous leukemia, acute lymphoblastic leukemia, and non-Hodgkin's lymphoma.

    摘要翻译： 本发明的特征在于在适应性干细胞移植之前调理患者的方法。 第一种方法涉及用淋巴消融方案治疗患者，所述方案使患者的造血干细胞的功能群恢复。 第二种方法涉及用清髓疗法治疗患者，相反，患者的T淋巴细胞群体的功能群体保留。 在两种方法中，患者在调理方案后施用来自供体的干细胞制剂以诱导宿主抗供体无应答。 患者也可以施用同种异体细胞疗法。 本发明还提供了制备患者特异性异基因干细胞制剂的方法。

    DEVICES AND METHODS FOR DETECTION OF INTERNAL BLEEDING AND HEMATOMA
    10.
    发明公开
    DEVICES AND METHODS FOR DETECTION OF INTERNAL BLEEDING AND HEMATOMA 审中-公开
    设备和检测方法的内部出血和瘀斑

    公开(公告)号：EP2861132A4

    公开(公告)日：2016-01-20

    申请号：EP13804355

    申请日：2013-06-13

    申请人： HADASIT MED RES SERVICE

    发明人： NAHMAN DEAN ,  ILAN YARON ,  BEN OREN ILAN ,  BAR-ILAN YARON ,  CHEN SHMUEL

    IPC分类号： A61B5/00 ,  A61B5/02 ,  A61B5/05

    CPC分类号： A61B5/02042 ,  A61B5/0075 ,  A61B5/4875 ,  A61B5/6833 ,  A61B2505/05

    摘要： A device for detection of internal bleeding in a patient's body is provided. An optical interface for transmitting IR light through an area of a skin of a patient and to collect IR light from the area of the skin, is provided. In some embodiments the optical interface includes one or more delivery components and one or more collection components. The delivery component includes a plurality of first optical channels configured to transmit the IR light through a plurality of respective first sub-areas on the area of the skin, into an internal layer of the body. The collection component includes a plurality of second optical channels, configured to collect IR light from a plurality of respective second sub-areas on the area of the skin.